# Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

> **NCT01928940** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** dabrafenib
- **DRUG:** trametinib

## Key facts

- **NCT ID:** NCT01928940
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-15
- **Primary completion:** 2014-09-18
- **Final completion:** 2016-07-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928940, "Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01928940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*